Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
SIRT1 Inhibitor
SIRT1-IN-3 is a selective inhibitor of SIRT1, exhibiting an IC50 value of 4.2 μM. This compound effectively modulates SIRT1 activity, making it a valuable tool for studies investigating the role of SIRT1 in various biological processes. Research applications include the exploration of SIRT1's involvement in metabolism, aging, and stress response pathways. -
SIRT1 Inhibitor
SIRT1-IN-2 is a potent and selective inhibitor of SIRT1 (silent information regulator 1), demonstrating an IC50 value of 1.6 μM. This compound plays a critical role in research focused on understanding the regulation of cellular metabolism, aging, and stress response pathways. Its specific inhibition of SIRT1 makes it a valuable tool for studying related biological processes and therapeutic interventions. -
Sirt2 Inhibitor
Sirt2-IN-2 is a selective inhibitor of the Sirtuin 2 (Sirt2) enzyme, exhibiting an IC50 of 0.118 μM. This compound is instrumental in research aimed at studying the role of Sirt2 in cellular processes and its implications in neurodegenerative diseases. Its use facilitates investigations into the potential therapeutic effects of Sirt2 modulation. -
Sirt2 inhibitor
SirReal-1 is a selective inhibitor of SIRT2, with an IC50 of 3.7 μM. This compound is utilized in research to investigate the biological role of SIRT2 in various cellular processes and its potential implications in cancer and neurodegenerative diseases. SirReal-1 serves as a valuable tool for elucidating the mechanisms of SIRT2-related signaling pathways. -
Sirtuin Inhibitor
Sirtuin-1 Inhibitor 1 is a selective inhibitor of Sirtuin-1, a key regulator in metabolic processes and cellular aging. This compound demonstrates potential in the study of obesity-related diabetes and age-associated diseases by modulating the activity of Sirtuin-1. Its application in research can enhance understanding of metabolic disorders and the molecular underpinnings of aging. -
SIRT2 Inhibitor
SIRT2-IN-11 is a selective inhibitor of the SIRT2 enzyme, exhibiting an IC50 value of 18.5 μM. This compound induces apoptosis in a p53-dependent manner, leading to the upregulation of CDKN1A, PUMA, and NOXA, along with increased p53 acetylation. SIRT2-IN-11 is a valuable tool for investigating p53-related cancer mechanisms and therapeutic strategies. -
SIRT2 Inhibitor
AC-93253 is a potent and selective inhibitor of SIRT2, achieving an IC50 value of 6 μM. This compound is instrumental in investigating the role of SIRT2 in tumor biology and may aid in the development of therapeutic strategies targeting SIRT2-related pathways in cancer research. Its specificity enhances the potential for targeted studies in cellular and molecular biology. -
SIRT2 Inhibitor
MIND4-19 is a selective inhibitor of SIRT2, demonstrating an IC50 value of 7.0 μM. This compound is primarily utilized in research related to Huntington's disease, offering insights into the therapeutic potential of SIRT2 modulation in neurodegenerative disorders. Its potency and target specificity make MIND4-19 a valuable tool for studying the role of SIRT2 in disease mechanisms and potential treatments. -
Sirtuin Inhibitor
Z26395438 is a potent inhibitor of Sirtuin-1, exhibiting an IC50 value of 1.6 μM. This compound is instrumental in research involving metabolic regulation, aging, and cellular stress responses. Its ability to modulate Sirtuin activity highlights its potential applications in studying various physiological and pathological processes. -
SIRT1 Inhibitor
CHIC35 is a selective inhibitor of SIRT1, exhibiting an IC50 of 0.124 μM. It demonstrates preferential inhibition of SIRT1 over SIRT2 (IC50=2.8 μM) and SIRT3 (IC50>100 μM). This compound is recognized for its anti-inflammatory properties and is applicable in research related to CHARGE syndrome. -
SIRT Inhibitor
SIRT1/2/3-IN-2 is a potent inhibitor of SIRT1, SIRT2, and SIRT3, exhibiting inhibition rates of 27%, 72%, and 71% respectively at a concentration of 200 μM. This compound is instrumental in studying the roles of sirtuins in various biological processes, particularly their involvement in cancer biology. SIRT3, known as a potential tumor suppressor or promoter, has been linked to lymph node-positive breast cancer and oral squamous cell carcinoma, making SIRT1/2/3-IN-2 valuable for cancer research applications. -
SIRT2 Inhibitor
SIRT2-IN-10 is a selective inhibitor of SIRT2, exhibiting an inhibitory concentration (IC50) of 1.3 μM. This compound is instrumental in studying its role in cancer pathology and neurodegenerative disorders, enabling research into potential therapeutic applications. Its ability to modulate SIRT2 activity makes it a valuable tool for investigating cellular mechanisms and disease progression. -
SIRT7 Inhibitor
Epigenetic factor-IN-1 is a selective SIRT7 inhibitor that plays a crucial role in modulating epigenetic regulation. It demonstrates a strong binding affinity for the SIRT7 protein, making it an important tool for exploring the mechanisms of epigenetic modifications. This compound is particularly relevant for liver cancer research, providing insights into the role of SIRT7 in cancer biology and therapeutic development. -
sirtuin SirT2 Inhibitor
Tenovin-D3 hydrochloride is a selective inhibitor of the sirtuin SirT2, which plays a crucial role in cellular regulation. This compound has been shown to enhance the expression of p21 (CDKN1A) independently of the p53 pathway. It is suitable for research applications focused on aging, cancer biology, and the modulation of cellular stress responses to explore the therapeutic potential of sirtuin inhibition. -
SIRT2 Inhibitor
Sirt2-IN-6 is a potent and selective inhibitor of SIRT2, exhibiting an IC50 of 0.815 μM. It demonstrates significant biological activity in modulating SIRT2-related pathways and is valuable for cancer research applications. This compound facilitates the exploration of SIRT2's role in oncogenesis and therapeutic development. -
SIRT1/2 Inhibitor
hsa62 is a dual inhibitor targeting SIRT1 and SIRT2, demonstrating IC50 values of 1.3 μM and 5.5 μM, respectively. This compound effectively modulates the activity of sirtuins, enzymes involved in various cellular processes, including metabolism and aging. hsa62 is suitable for research investigating the role of sirtuins in cellular regulation, disease models, and therapeutic applications. -
SIRT5 Inhibitor
SIRT5 Inhibitor 6 is a selective and potent inhibitor of SIRT5 that functions through a substrate-competitive mechanism, demonstrating an IC50 value of 3.0 μM. This compound shows promise in therapeutic applications for septic acute kidney injury (AKI) in vivo, making it a valuable tool for research in kidney health and related pathologies. -
SIRT1/SIRT2 Inhibitor
Guttiferone G is a selective inhibitor of the human SIRT1 and SIRT2 deacetylases, exhibiting IC50 values of 9 μM and 22 μM, respectively. This compound demonstrates weak cytotoxicity in the A2780 human ovarian cancer cell line, with an IC50 of 8.0 μg/mL. Guttiferone G is derived from Garcinia macrophylla and may serve as a valuable tool in research studies exploring SIRT1 and SIRT2 modulation in cellular processes. -
SIRT5 Inhibitor
SIRT5 inhibitor 5 is a potent inhibitor of the SIRT5 enzyme, exhibiting an IC50 value of 0.21 µM. This compound functions as a substrate-competitive inhibitor, specifically not occupying the NAD+-binding pocket, thereby modulating SIRT5 activity. SIRT5 inhibitor 5 is valuable in research focused on elucidating the role of SIRT5 in metabolic pathways and providing insights into its potential implications in various diseases. -
SIRT5 Inhibitor
SIRT5 Inhibitor 4 is a selective inhibitor of the SIRT5 enzyme, demonstrating an IC50 value of 26.4 μM. This compound exhibits minimal activity against other SIRT subtypes, with an IC50 greater than 400 μM, underscoring its specificity. It serves as a valuable tool for investigating the biological roles of SIRT5 in metabolic regulation and related pathways. Research applications include studying SIRT5's involvement in cellular processes and potential therapeutic targets in metabolic disorders. -
SIRT2 Inhibitor
AGK7 is a selective inhibitor of sirtuin 2 (SIRT2), demonstrating significant neuroprotective effects in the context of Parkinson's disease. This compound has been shown to alleviate alpha-synuclein toxicity and improve inclusion morphology in cellular models. In addition, AGK7 effectively protects against dopaminergic cell death in both in vitro studies and Drosophila models, making it a valuable tool for researching neurodegenerative disorders. -
SIRT3 Inhibitor
SIRT-IN-5 is a selective inhibitor of SIRT3, demonstrating an IC50 value of 2.88 μM. This compound has been shown to promote the differentiation of multiple myeloma cells, facilitating increased expression of differentiation antigens such as CD49e, as well as enhancement of human immunoglobulin light chains λ and κ. SIRT-IN-5 is a valuable tool in research focused on the modulation of cellular differentiation processes in hematological malignancies. -
SIRT1/2 Inhibitor
Sirtuin-IN-1 is a selective inhibitor of SIRT1 and SIRT2, with IC50 values of 6.2 μM and 4.2 μM, respectively. This compound has been shown to induce G1 phase cell cycle arrest, demonstrating its potential as an anti-cancer agent. Sirtuin-IN-1 is particularly effective against glioma, making it a valuable tool for research into cancer therapeutics and the exploration of sirtuin-related biological pathways. -
SIRT1 Inhibitor
Sirtuin Modulator 4 is a selective SIRT1 inhibitor, demonstrating an EC50 value of 51-100 μM. This compound plays a critical role in modulating cellular pathways associated with lifespan extension and offers potential in researching a variety of conditions, including diabetes, obesity, neurodegenerative diseases, cardiovascular disorders, inflammation, and cancer. Its ability to inhibit SIRT1 makes it a valuable tool for studying the therapeutic implications of sirtuin regulation in metabolic and age-related diseases. -
SIRT2 Inhibitor
SIRT2-IN-14 is a selective inhibitor of SIRT2, demonstrating an IC50 value of 0.196 μM. This compound effectively modulates SIRT2 activity, making it a valuable tool for studying the role of SIRT2 in various biological pathways. Research applications may include investigations into neurodegenerative diseases, cancer biology, and cellular metabolism, providing insights into the therapeutic potential of targeting SIRT2. -
SIRT5 Inhibitor
SIRT5 inhibitor 2 is a selective inhibitor of the SIRT5 enzyme, exhibiting an IC50 value of 2.3 μM. It effectively inhibits SIRT5-dependent desuccinylation processes, making it a valuable tool for investigating the roles of SIRT5 in various biological contexts. This compound is suitable for research applications focusing on cancer biology and neurodegenerative diseases, aiding in the exploration of therapeutic strategies targeting SIRT5 activity. -
SIRT1 Inhibitor
ZINC08792355 is a selective SIRT1 inhibitor that plays a crucial role in the regulation of cellular processes associated with aging, metabolic disorders, and oncogenesis. This compound facilitates the exploration of SIRT1-related pathways in research on age-related diseases, diabetes, and cancer, making it a valuable tool for investigators studying these important biological phenomena. -
SIRT2 Inhibitor
SR94 is a selective SIRT2 inhibitor that features a unique six-membered ring structure with variable R2 substituents. This compound demonstrates potential in the investigation of cancer, ischemia-reperfusion injury, and neurodegenerative diseases. Its targeted inhibition of SIRT2 makes it a valuable tool for understanding the role of this enzyme in various biological processes and disease states. -
SIRT5 Inhibitor
SIRT5 Inhibitor 7 is a selective substrate-competitive inhibitor targeting SIRT5, known for its anti-inflammatory properties. This compound effectively regulates protein succinylation and reduces the release of pro-inflammatory cytokines, offering potential renal protective effects. SIRT5 Inhibitor 7 demonstrates notable in vivo efficacy in mouse models of acute kidney injury induced by lipopolysaccharide (LPS) and cecal ligation/perforation (CLP), making it a valuable tool for researching sepsis-related kidney damage. -
SIRT1 Inhibitor
ZINC08792229 is a potent inhibitor of SIRT1, a nicotinamide adenine dinucleotide (NAD+)-dependent deacetylase playing a crucial role in cellular regulation. This compound exhibits significant biological activity that may contribute to research on SIRT1-related diseases, including aging, diabetes, and cancer. It serves as a valuable tool for exploring the therapeutic potential of targeting SIRT1 in various pathological conditions. -
SIRT1/SIRT2 Inhibitor
Aristoforin, a hypericin derivative, selectively inhibits SIRT1 and SIRT2, resulting in G1 phase cell cycle arrest. This compound also scavenges hydroxyl free radicals and demonstrates protective effects against Fe2+-induced DNA breakage. Aristoforin is valuable for research in the context of breast cancer and colon adenocarcinoma studies. -
SIRT3 Inhibitor
SIRT3-IN-2 is a selective inhibitor of the SIRT3 enzyme, demonstrating a reduction of SIRT3 activity by 39% at a concentration of 200 µM. This compound is valuable for investigations into metabolic homeostasis and its implications in tumor suppression. SIRT3-IN-2 can be utilized in research aimed at understanding the regulatory roles of sirtuins in cellular metabolism and cancer biology. -
SIRT2 Inhibitor
SIRT2-IN-15 is a selective inhibitor of the SIRT2 deacetylase and deamyloacylase enzymes, demonstrating IC50 values of 7 μM and 37 μM, respectively. This compound modulates cellular acetylation states, making it a valuable tool for investigating the roles of SIRT2 in various biological processes, including neurodegenerative diseases, cancer metabolism, and aging. SIRT2-IN-15 can be utilized in research applications focusing on the molecular mechanisms of SIRT2-related pathways and potential therapeutic targets. -
SIRT2 Inhibitor
A2B57 is a selective inhibitor of SIRT2, exhibiting an IC50 value of 6.3 µM. This compound effectively modulates the activity of SIRT2, making it a valuable tool for exploring the role of this enzyme in various biological processes. Its application extends to studies in neurodegeneration, metabolism, and cellular stress responses, providing insights into SIRT2-related pathways. -
SIRT1/2/3 Inhibitor
SIRT-IN-6 is a pan-inhibitor targeting SIRT1, SIRT2, and SIRT3, with IC50 values exceeding 50 μM. This compound is valuable for studying its effects in metabolic, inflammatory, oncologic, and neurodegenerative disorders. Its broad inhibition profile makes it a suitable tool for elucidating the roles of sirtuins in various biological processes and disease states. -
SIRT2 Inhibitor
A1B11 is a selective inhibitor of Sirtuin 2 (SIRT2) with an IC50 value of 5.3 μM. This compound is primarily utilized in research focused on neurodegenerative diseases, where SIRT2 modulation plays a critical role in the underlying mechanisms of pathology. A1B11 provides a valuable tool for investigating the therapeutic potential of SIRT2 inhibition in various neurodegenerative conditions. -
SIRT1/2 Inhibitor
Sirt1/2-IN-1 is a selective inhibitor of SIRT1 and SIRT2, exhibiting IC50 values of 1.81 and 2.10 µg/mL, respectively, while also inhibiting SIRT3 with an IC50 of 20.5 µg/mL. This compound induces hyperacetylation of α-tubulin, with an IC50 of 32.05 µg/mL, demonstrating its potential for modulating protein acetylation. Sirt1/2-IN-1 is particularly relevant in cancer research, showcasing significant anticancer activity that supports its use in investigating therapeutic strategies targeting sirtuin pathways.
